Key Facts Surrounding This News Item
- MGTX had returned 0.00% year-to-date leading up to today’s news, versus a +4.37% return from the benchmark S&P 500 during the same period.
More Info About MeiraGTx Holdings plc – Ordinary Shares (MGTX)
MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom. View our full MGTX ticker page with ratings, news, and more.